Shanghai Hile Bio-Technology Co.,Ltd (China)

Shanghai Hile Bio-Technology Co., Ltd (SH:603718), also known as the Company, is a specialized animal biological product manufacturing enterprise located in Shanghai. The company was established in 1981 and was formerly known as Shanghai Songjiang Biological Pharmaceutical Factory. It is an approved designated enterprise for the production of animal biological products by the Ministry of Agriculture in Shanghai and is also a major animal epidemic prevention and control production base established by the Ministry of Agriculture. The company offers a complete product line with a total of 23 products in the poultry and livestock categories. In May 2015, the company successfully listed on the domestic A-share main board market, with a total share capital of 64.4 million shares. The company is recognized as a high-tech enterprise in Shanghai, a key high-tech enterprise under the Torch Program of the National Ministry of Science and Technology, a key leading enterprise in agricultural industrialization in Shanghai, a civilized unit in Shanghai, and a creditworthy enterprise in Shanghai. The company's R&D center has been recognized as the Shanghai Enterprise Technology Center, Shanghai Animal Biological Product Engineering Technology Research Center, Shanghai Municipal Professional Technical Service Platform for Animal Vaccine Manufacturing Processes, and Shanghai Academician Expert Workstation. The company owns 25 registered trademarks, 3 invention patents, and 42 utility model patents. One of its trademarks, "Haili Bio," has been recognized as a famous trademark in Shanghai. The company's pig vaccine product has been awarded the "Shanghai Famous Brand" title. The company holds various production and operation qualification certificates, including the veterinary GMP certificate, veterinary drug production license, laboratory animal license, and veterinary drug operation license. It has 6 GMP production lines and independently produces vaccines for livestock and poultry. The company is committed to building a research system that combines independent research and development with industry-academia-research cooperation. It has established stable cooperative relationships with research institutions and universities such as the China Institute of Veterinary Drug Control, Chinese Academy of Sciences, Shanghai Academy of Agricultural Sciences, Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, Beijing Academy of Agriculture and Forestry Sciences, Jiangsu Academy of Agricultural Sciences, Nanjing Agricultural University, Henan Agricultural University, Huazhong Agricultural University, Zhejiang University, and Jiangxi Agricultural University. Through collaborative research and technology licensing, the company has achieved multiple non-patented technologies in the field of animal vaccines and rapidly realized the transformation of high-tech achievements. Since its establishment, the company has adhered to the path of technological innovation, market-oriented, and product-based development. Its sales network covers the whole country, and its sales performance has steadily increased. With a people-oriented talent strategy, the company has established a market-oriented marketing team, a skilled R&D team, and a skilled employee team. The company is dedicated to providing comprehensive solutions and authoritative veterinary expert services to prevent animal diseases, improve animal health, and enhance the production efficiency of animal husbandry owners. To meet market demand, the company will continue to focus on independent innovation and the development of high-tech industrialization, striving to become a leader in the domestic animal health industry. While developing itself, the company actively engages in deep cooperation with global industry enterprises and seeks development in the field of human health. Its subsidiary, Yangling Jinhai Biotechnology Co., Ltd., is one of the domestic foot-and-mouth disease vaccine production companies. It uses a fully suspended and highly purified production process technology for foot-and-mouth disease vaccine production, making positive contributions to the prevention of foot-and-mouth disease in China. In June 2018, the company completed the acquisition of Shanghai Jiemeng Biotechnology Co., Ltd., a high-tech scientific and technological enterprise engaged in the research, development, and production of in vitro diagnostic reagents for human use. It also cooperated with the global biopharmaceutical service provider WuXi Biologics (02269.HK) to establish WuXi Hilde, dedicated to building an integrated capability and technology platform for the global vaccine industry, providing contract development and manufacturing organization (CDMO) services for vaccines, and empowering global vaccine industry research and production. Currently, the company is solidifying its main business foundation while actively implementing the dual-wheel drive strategy of "animal health + human health," which is conducive to the company's breakthrough in existing sub-industry restrictions and achieving stronger and larger development on a broader platform.